Novel formulation of curcumin-loaded chlorhexidine drug combined with gold nanoparticles for effective therapeutic agent against urinary tract infections.

Abstract

Aim: This study investigates a novel treatment for urinary tract infections (UTIs) caused by Staphylococcus aureus, Escherichia coli, and Klebsiella pathogenic bacterial strains.

Methods: The Cur/Chx/Au composite matrix was synthesised in one pot by solution reduction and examined for functional groups and surface morphology by FT-IR, UV-DRS, HR-TEM, and TGA. In vitro, microbial growth inhibition evaluation and pathogen biofilm studies assessed the composite's antibacterial capacity.

Results: Cur/Chx/Au exhibit mean diameter from 30 ± 5.2 nm, PDI 0.50 ± 0.05, and a zeta potential of -9.56 ± 1.84. The inhibition zones for S. aureus and E. coli were 16 ± 1.2 mm and 14 ± 0.8 mm, respectively, with an anti-inflammatory inhibition rate of 89.96%. The composite material's biocompatibility was further tested utilising in-vitro MTT, cell proliferation, and wound scratch assays in NHI 3T3 cells.

Conclusion: Our findings demonstrate that the combination of Cur/Chx/Au composite matrix is a promising formulation for UTI treatment.